The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.
An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element
Open accessAbstract
In certain human cancers, the expression of critical oncogenes is driven from large regulatory elements, called super-enhancers, that recruit much of the cell’s transcriptional apparatus and are defined by extensive acetylation of histone H3 lysine 27 (H3K27ac). In a subset of T-cell acute lymphoblastic leukemia (T-ALL) cases, we found that heterozygous somatic mutations are acquired that introduce binding motifs for the MYB transcription factor in a precise noncoding site, which creates a super-enhancer upstream of the TAL1 oncogene. MYB binds to this new site and recruits its H3K27 acetylase–binding partner CBP, as well as core components of a major leukemogenic transcriptional complex that contains RUNX1, GATA-3, and TAL1 itself. Additionally, most endogenous super-enhancers found in T-ALL cells are occupied by MYB and CBP, which suggests a general role for MYB in super-enhancer initiation. Thus, this study identifies a genetic mechanism responsible for the generation of oncogenic super-enhancers in malignant cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The ability of AlphaGenome to simultaneously score variant effects across all modalities accurately recapitulates the mechanisms of clinically relevant variants near the TAL1 oncogene6.”
From Advancing regulatory variant effect prediction with AlphaGenome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Detailed ALT–REF predictions for an oncogenic insertion (chr. 1: 47239296: C>ACG) characterized in ref. 6. Shown are differences between AlphaGenome predictions between the ALT and REF sequences of the variant in CD34+ CMP tracks. The ALT sequence increases expression of the TAL1 gene 7.5 kb away.”
From Advancing regulatory variant effect prediction with AlphaGenome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We evaluated three groups of gain-of-function mutations affecting the TAL1 gene in T cell acute lymphoblastic leukaemia (T-ALL): a cluster of 5′ neo-enhancer mutations upstream of the TAL1 TSS6,33, an intronic single-nucleotide variant (SNV)34 and a 3′ neo-enhancer35.”
From Advancing regulatory variant effect prediction with AlphaGenome (2026) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“By contrast, the alternative sequence introduced a MYB motif at the variant position predicted to increase TAL1 expression, chromatin accessibility and H3K27ac chromatin marks (Fig. 6e), as discovered previously6.”
From Advancing regulatory variant effect prediction with AlphaGenome (2026) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
The Human Genome Browser at UCSC
Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H., Zahler, A. M., & Haussler, A. D. (2002) · Genome Research · doi:10.1101/gr.229102 · Cited by 10,400
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Histone H3K27ac separates active from poised enhancers and predicts developmental state
Creyghton, M. P., Cheng, A. W., Welstead, G. G., Kooistra, T., Carey, B. W., Steine, E. J., Hanna, J., Lodato, M. A., Frampton, G. M., Sharp, P. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016071107 · Cited by 4,302
Self-citationSelective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
FIMO: scanning for occurrences of a given motif
Grant, C. E., Bailey, T. L., & Noble, W. S. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr064 · Cited by 4,247
Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
Whyte, W. A., Orlando, D. A., Hnisz, D., Abraham, B. J., Lin, C. Y., Kagey, M. H., Rahl, P. B., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.035 · Cited by 4,143
Self-citation
Flagged first, then by citations
1 of the 46 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 301–400 of 805
Staples, M. I., Frazer, C., Fawzi, N. L., & Bennett, R. J. (2023) · Nature Microbiology · doi:10.1038/s41564-022-01314-6 · Cited by 37
Transcription factor condensates and signaling driven transcription
Mann, R., & Notani, D. (2023) · Nucleus · doi:10.1080/19491034.2023.2205758 · Cited by 39
Super-enhancers and novel therapeutic targets in colorectal cancer
Liu, Q., Guo, L., Lou, Z., Xiang, X., & Shao, J. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04673-4 · Cited by 31
Effects of super-enhancers in cancer metastasis: mechanisms and therapeutic targets
Liu, S., Dai, W., Jin, B., Jiang, F., Huang, H., Hou, W., Lan, J., Jin, Y., Peng, W., & Pan, J. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02033-8 · Cited by 35
Signatures of accelerated somatic evolution in gene promoters in multiple cancer types
Smith, K. S., Yadav, V. K., Pedersen, B. S., Shaknovich, R., Geraci, M. W., Pollard, K. S., & De, S. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv419 · Cited by 31
JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia
Mansour, M. R., He, S., Li, Z., Lobbardi, R., Abraham, B. J., Hug, C. B., Rahman, S., León, T. E., Kuang, Y., Zimmerman, M. W., et al. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20170484 · Cited by 32
Self-citationAlAbdi, L., Saha, D., He, M., Dar, M. S., Utturkar, S. M., Sudyanti, P. A., McCune, S., Spears, B. H., Breedlove, J. A., Lanman, N. A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.11.040 · Cited by 29
Intrinsic transcriptional heterogeneity in neuroblastoma guides mechanistic and therapeutic insights
Shendy, N. A. M., Zimmerman, M. W., Abraham, B. J., & Durbin, A. D. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100632 · Cited by 34
Self-citationTypical Enhancers, Super-Enhancers, and Cancers
Koutsi, M. A., Pouliou, M., Champezou, L., Vatsellas, G., Giannopoulou, A.-I., Piperi, C., & Agelopoulos, M. (2022) · Cancers · doi:10.3390/cancers14184375 · Cited by 28
Liang, Y. J., Xu, P., Zou, Q., Luo, H., & Yu, W. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.09.001 · Cited by 32
Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML
Mulet‐Lazaro, R., van Herk, S., Erpelinck-Verschueren, C. A. J., Bindels, E. M., Sanders, M. A., Vermeulen, C., Renkens, I., Valk, P. J. M., Melnick, A. M., de Ridder, J., et al. (2021) · Blood · doi:10.1182/blood.2020009244 · Cited by 32
Current and emerging therapeutic approaches for T‐cell acute lymphoblastic leukaemia
Pocock, R., Farah, N., Richardson, S. E., & Mansour, M. R. (2021) · British Journal of Haematology · doi:10.1111/bjh.17310 · Cited by 30
Self-citationCis-acting super-enhancer lncRNAs as biomarkers to early-stage breast cancer
Ropri, A. S., DeVaux, R. S., Eng, J., Chittur, S. V., & Herschkowitz, J. I. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01479-8 · Cited by 30
Wyn, J. D., Zimmerman, M. W., Weichert‐Leahey, N., Nunes, C., Cheung, B. B., Abraham, B. J., Beckers, A., Volders, P., Decaesteker, B., Carter, D. R., et al. (2021) · Cancers · doi:10.3390/cancers13194783 · Cited by 30
Self-citationTranscriptomics paving the way for improved diagnostics and precision medicine of acute leukemia
Lilljebjörn, H., Orsmark‐Pietras, C., Mitelman, F., Andersson, A., & Fioretos, T. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.09.013 · Cited by 33
Super-enhancers conserved within placental mammals maintain stem cell pluripotency
Zhang, J., Zhou, Y., Yue, W., Zhu, Z., Wu, X., Yu, S., Shen, Q., Pan, Q., Xu, W., Zhang, R., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204716119 · Cited by 27
TAL1 activation in T-cell acute lymphoblastic leukemia: a novel oncogenic 3’ neo-enhancer
Smith, C., Goyal, A., Weichenhan, D., Allemand, E., Mayakonda, A., Toprak, U., Riedel, A., Balducci, E., Manojkumar, M., Pejkovska, A., et al. (2023) · Haematologica · doi:10.3324/haematol.2022.281583 · Cited by 30
Chakraborty, C., Nissen, I., Vincent, C. A., Hägglund, A., Hörnblad, A., & Remeseiro, S. (2023) · Nature Communications · doi:10.1038/s41467-023-41919-x · Cited by 30
Extraordinary Cancer Epigenomics: Thinking Outside the Classical Coding and Promoter Box
Murtha, M. J., & Esteller, M. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.08.004 · Cited by 30
Beyond DNA: the Role of Epigenetics in the Premalignant Progression of Breast Cancer
DeVaux, R. S., & Herschkowitz, J. I. (2018) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-018-9414-2 · Cited by 32
Dysregulated Transcriptional Control in Prostate Cancer
Baumgart, S. J., Nevedomskaya, E., & Haendler, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122883 · Cited by 30
Determinants and role of chromatin organization in acute leukemia
Fang, C., Rao, S., Crispino, J. D., & Ntziachristos, P. (2020) · Leukemia · doi:10.1038/s41375-020-0981-z · Cited by 30
Super-enhancer-mediated core regulatory circuitry in human cancer
Jiang, Y. Y., Jiang, Y., & Lin, D. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.05.006 · Cited by 33
Lu, B., Wei, J., Zhou, H., Chen, J., Li, Y., Ye, L., Zhao, W., & Wu, S. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04983-7 · Cited by 29
Kent, D., Marchetti, L., Mikulášová, A., Russell, L. J., & Rico, D. (2023) · BioEssays · doi:10.1002/bies.202200239 · Cited by 31
microRNAs regulate TAL1 expression in T-cell acute lymphoblastic leukemia
Correia, N., Melão, A., Póvoa, V., Sarmento, L. M., de Cedrón, M. G., Malumbres, M., Enguita, F. J., & Barata, J. T. (2016) · Oncotarget · doi:10.18632/oncotarget.6987 · Cited by 28
Jiang, J., Liu, L., Gao, Y., Shi, L., Lǐ, Y., Liang, W., & Sun, D. (2019) · BMC Genetics · doi:10.1186/s12863-019-0751-y · Cited by 28
Diedrich, J. D., Dong, Q., Ferguson, D. C. J., Bergeron, B. P., Autry, R. J., Qian, M., Yang, W., Smith, C. J., Papizan, J. B., Connelly, J. P., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01209-1 · Cited by 27
Ling, X., Liu, X., Jiang, S., Fan, L., & Ding, J. (2022) · Cell Regeneration · doi:10.1186/s13619-022-00145-4 · Cited by 29
Motif signatures in stretch enhancers are enriched for disease-associated genetic variants
Quang, D. X., Erdos, M. R., Parker, S. C. J., & Collins, F. S. (2015) · Epigenetics & Chromatin · doi:10.1186/s13072-015-0015-7 · Cited by 28
Haider, Z., Larsson, P. G., Landfors, M., Köhn, L., Schmiegelow, K., Flægstad, T., Kanerva, J. A., Heyman, M. M., Hultdin, M., & Degerman, S. (2018) · Cancer Medicine · doi:10.1002/cam4.1917 · Cited by 28
CRISPRi-mediated functional analysis of NKX2-1-binding sites in the lung
Stuart, W. D., Fink-Baldauf, I. M., Tomoshige, K., Guo, M., & Maeda, Y. (2021) · Communications Biology · doi:10.1038/s42003-021-02083-4 · Cited by 24
Lim, S. W., Tan, K. J., Osman, M. A., Maran, S., Lim, E. C., Lai, K., Yap, W.-S., & Afizan, N. A. R. N. M. (2021) · Scientific Reports · doi:10.1038/s41598-021-03624-x · Cited by 27
Neyret‐Kahn, H., Fontugne, J., Meng, X. Y., Groeneveld, C. S., Cabel, L., Ye, T., Guyon, E., Krucker, C., Dufour, F., Chapeaublanc, E., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02662-1 · Cited by 27
Botten, G., Zhang, Y., Dudnyk, K., Kim, Y., Liu, X., Sanders, J. T., Imanci, A., Droin, N., Cao, H., Kaphle, P., et al. (2022) · Blood · doi:10.1182/blood.2022017555 · Cited by 29
O’Connor, D., Demeulemeester, J., Conde, L., Kirkwood, A. A., Fung, K. T. M., Papaleonidopoulou, F., Bloye, G., Farah, N., Rahman, S., Hancock, J. P., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02734 · Cited by 28
Self-citationEtiology of super-enhancer reprogramming and activation in cancer
Zhou, R. W., & Parsons, R. E. (2023) · Epigenetics & Chromatin · doi:10.1186/s13072-023-00502-w · Cited by 31
MLL-AF4 cooperates with PAF1 and FACT to drive high-density enhancer interactions in leukemia
Crump, N. T., Smith, A., Godfrey, L., Dopico-Fernandez, A. M., Denny, N., Harman, J. R., Hamley, J. C., Jackson, N., Chahrour, C., Riva, S. G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40981-9 · Cited by 28
Buckley, M., Yeung, D. T. O., White, D. L., & Eadie, L. N. (2025) · Leukemia · doi:10.1038/s41375-025-02599-2 · Cited by 26
Falkenberg, K. D., Jakobs, A., Matern, J. C. J., Dörner, W., Uttarkar, S., Trentmann, A., Steinmann, S., Coulibaly, A., Schomburg, C., Mootz, H. D., et al. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.05.003 · Cited by 26
Wiggers, C. R. M., Baak, M. L., Sonneveld, E., Nieuwenhuis, E. E. S., Bartels, M., & Creyghton, M. P. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.012 · Cited by 25
Targeting complexes of super‑enhancers is a promising strategy for cancer therapy (Review)
Zheng, C., Liu, M., & Fan, H. (2020) · Oncology Letters · doi:10.3892/ol.2020.11855 · Cited by 27
Nair, S. J., Suter, T., Wang, S. S., Lu, Y., Yang, F., & Rosenfeld, M. G. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.05.015 · Cited by 27
Luo, H., Li, Y., Huan, L., Ding, P., Yu, Y., & Luo, L. (2023) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2023.107905 · Cited by 26
c-Myb Binding Sites in Haematopoietic Chromatin Landscapes
Bengtsen, M., Klepper, K., Gundersen, S., Cuervo, I., Drabløs, F., Hovig, E. J., Sandve, G. K., Gabrielsen, O. S., & Eskeland, R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133280 · Cited by 26
Coulibaly, A., Haas, A., Steinmann, S., Jakobs, A., Schmidt, T. J., & Klempnauer, K. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190934 · Cited by 26
Yusenko, M. V., Jakobs, A., & Klempnauer, K. (2018) · Scientific Reports · doi:10.1038/s41598-018-31620-1 · Cited by 26
Vähärautio, A., & Taipale, J. (2014) · Science · doi:10.1126/science.aaa3247 · Cited by 25
Limb girdle myasthenia with digenic RAPSN and a novel disease gene AK9 mutations
Lam, C., Wong, K. S., Leung, H., & Law, C. Y. (2016) · European Journal of Human Genetics · doi:10.1038/ejhg.2016.162 · Cited by 25
Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy
Kadia, T. M., Kantarjian, H. M., & Konopleva, M. Y. (2019) · Oncotarget · doi:10.18632/oncotarget.26579 · Cited by 25
Role of Enhancers in Development and Diseases
Maurya, S. S. (2021) · Epigenomes · doi:10.3390/epigenomes5040021 · Cited by 26
Altered TERT promoter and other genomic regulatory elements: occurrence and impact
Heidenreich, B., & Kumar, R. (2017) · International Journal of Cancer · doi:10.1002/ijc.30735 · Cited by 26
Occurrence, functionality and abundance of the TERT promoter mutations
Rachakonda, S. P., Hoheisel, J. D., & Kumar, R. (2021) · International Journal of Cancer · doi:10.1002/ijc.33750 · Cited by 27
Precision oncology in Latin America: current situation, challenges and perspectives
Calderón-Aparicio, A., & Orué, A. (2019) · ecancermedicalscience · doi:10.3332/ecancer.2019.920 · Cited by 25
Multi-omic approaches to improve outcome for T-cell acute lymphoblastic leukemia patients
van der Zwet, J. C. G., Cordo’, V., Canté-Barrett, K., & Meijerink, J. P. P. (2019) · Advances in Biological Regulation · doi:10.1016/j.jbior.2019.100647 · Cited by 24
He, B., Gao, P., Ding, Y., Chen, C.-H., Chen, G., Chen, C., Kim, H., Tasian, S. K., Hunger, S. P., & Tan, K. (2020) · Science Advances · doi:10.1126/sciadv.aba3064 · Cited by 25
Self-citationMikulášová, A., Kent, D., Trevisán-Herraz, M., Karataraki, N., Fung, K. T. M., Ashby, C., Cieślak, A., Yaccoby, S., van Rhee, F., Zangari, M., et al. (2021) · Genome Research · doi:10.1101/gr.276042.121 · Cited by 22
A Tumor Suppressor Enhancer of PTEN in T-cell Development and Leukemia
Tottone, L., Lancho, O., Loh, J.-W., Singh, A., Kimura, S., Roels, J., Kuchmiy, A. A., Strubbe, S., Lawlor, M. A., da Silva-Diz, V., et al. (2020) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0201 · Cited by 24
Yusenko, M. V., Trentmann, A., Casolari, D. A., Ghani, L. A., Lenz, M., Horn, M., Dörner, W., Klempnauer, S., Mootz, H. D., Arteaga, M. F., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01800-x · Cited by 24
Proteasome inhibitors suppress MYB oncogenic activity in a p300-dependent manner
Yusenko, M. V., Biyanee, A., Andersson, M. K., Radetzki, S., von Kries, J. P., Stenman, G., & Klempnauer, K. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.07.010 · Cited by 23
TAL1 cooperates with PI3K/AKT pathway activation in T-cell acute lymphoblastic leukemia
Thielemans, N., Demeyer, S., Mentens, N., Gielen, O., Provost, S., & Cools, J. (2022) · Haematologica · doi:10.3324/haematol.2021.279718 · Cited by 23
Song, H., Liu, Y., Tan, Y., Zhang, Y., Jin, W. Y., Chen, L., Wu, S., Yan, J., Li, J., Chen, Z., et al. (2022) · Blood · doi:10.1182/blood.2021014945 · Cited by 23
Superenhancers as master gene regulators and novel therapeutic targets in brain tumors
Zhuang, H.-H., Qu, Q., Teng, X.-Q., Dai, Y.-H., & Qu, J. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00934-0 · Cited by 24
Phase separation in gene transcription control
Li, C., Li, Z., Wu, Z., & Lu, H. (2023) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2023099 · Cited by 25
Saito, S., Kikuchi, J., Koyama, D., Sato, S., Koyama, H., Osada, N., Kuroda, Y., Akahane, K., Inukai, T., Umehara, T., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0919 · Cited by 23
Svetlichnyy, D., Imrichová, H., Fiers, M. W. E. J., Atak, Z. K., & Aerts, S. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004590 · Cited by 22
The molecular understanding of super-enhancer dysregulation in cancer.
Yoshino, S., & Suzuki, H. I. (2022) · PubMed Central · doi:10.18999/nagjms.84.2.216 · Cited by 23
Hidden modes of DNA binding by human nuclear receptors
Bhimsaria, D., Rodríguez‐Martínez, J. A., Méndez, J., Ghoshdastidar, D., Varadarajan, A., Bansal, M., Daniels, D. L., Ramanathan, P., & Ansari, A. Z. (2023) · Nature Communications · doi:10.1038/s41467-023-39577-0 · Cited by 21
EnDisease: a manually curated database for enhancer-disease associations
Zeng, W., Xu, M., & Jiang, R. (2019) · Database · doi:10.1093/database/baz020 · Cited by 21
Zhang, X., Wang, Y., Chiang, H.-C., Hsieh, Y.-P., Lu, C., Park, B. H., Jatoi, I., Jin, V. X., Hu, Y., & Li, R. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1132-1 · Cited by 22
Logic programming reveals alteration of key transcription factors in multiple myeloma
Miannay, B., Minvielle, S., Roux, O. H., Drouin, P., Avet‐Loiseau, H., Guérin‐Charbonnel, C., Gouraud, W., Attal, M., Facon, T. T. F., Munshi, N. C., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09378-9 · Cited by 22
Finding cancer driver mutations in the era of big data research
Poulos, R., & Wong, J. W. H. (2018) · Biophysical Reviews · doi:10.1007/s12551-018-0415-6 · Cited by 20
Functions and Clinical Significance of Super-Enhancers in Bone-Related Diseases
Qu, J., Ouyang, Z., Wu, W., Li, G., Wang, J., Lu, Q., & Li, Z. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00534 · Cited by 21
Super enhancers as master gene regulators in the pathogenesis of hematologic malignancies
Debek, S. M., & Juszczyński, P. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188697 · Cited by 23
Salma, M., Andrieu‐Soler, C., Deleuze, V., & Soler, É. (2023) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2023.102745 · Cited by 19
Super-Enhancers and Their Parts: From Prediction Efforts to Pathognomonic Status
Vasileva, A. V., Gladkova, M. G., Ashniev, G. A., Osintseva, E. D., Орлов, А. В., Kravchuk, E. V., Boldyreva, A., Burenin, A. G., Nikitin, P. I., & Orlova, N. N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063103 · Cited by 24
Tan, S. H., Yam, A. W. Y., Lawton, L. N., Wong, R. W. J., Young, R. A., Look, A. T., & Sanda, T. (2015) · Leukemia · doi:10.1038/leu.2015.195 · Cited by 21
Self-citationThe search for cis-regulatory driver mutations in cancer genomes
Poulos, R. C., Sloane, M. A., Hesson, L. B., & Wong, J. W. H. (2015) · Oncotarget · doi:10.18632/oncotarget.5085 · Cited by 21
Super enhancer associated RAI14 is a new potential biomarker in lung adenocarcinoma
Yuan, C., Hu, H., Kuang, M., Chen, Z., Tao, X., Fang, S., Sun, Y., Zhang, Y., & Chen, H. (2017) · Oncotarget · doi:10.18632/oncotarget.22165 · Cited by 21
Heyes, E. C., Schmidt, L., Manhart, G., Eder, T., Proietti, L., & Grebien, F. (2021) · Leukemia · doi:10.1038/s41375-021-01169-6 · Cited by 23
Hung, S., Saiakhova, A., Faber, Z. J., Bartels, C. F., Neu, D., Bayles, I., Ojo, E. O., Hong, E. S., Pontius, W., Morton, A. R., et al. (2019) · eLife · doi:10.7554/elife.40760 · Cited by 22
Transcription factor networks link B-lymphocyte development and malignant transformation in leukemiaPreprint
Sigvardsson, M. (2023) · Genes & Development · doi:10.1101/gad.349879.122 · Cited by 24
Neumann, M., Beder, T., Bastian, L., Hänzelmann, S., Bultmann, M., Wolgast, N., Hartmann, A., Trautmann, H., Ortiz-Tánchez, J., Schlee, C., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02264-0 · Cited by 20
Transcriptional enhancers: from prediction to functional assessment on a genome-wide scale
Tobias, I. C., Abatti, L. E., Moorthy, S. D., Mullany, S., Taylor, T., Khader, N., Filice, M., & Mitchell, J. A. (2020) · Genome · doi:10.1139/gen-2020-0104 · Cited by 25
Thillo, Q. V., Bie, J. D., Seneviratne, J. A., Demeyer, S., Omari, S. A., Balachandran, A., Zhai, V., Tam, W. L., Sweron, B., Geerdens, E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24442-9 · Cited by 20
Gomez, R. L., Woods, L. M., Ramachandran, R., Tayoun, A. N. A., Philpott, A., & Ali, F. R. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.943924 · Cited by 19
LncRNA SNHG1 regulates neuroblastoma cell fate via interactions with HDAC1/2
Hsu, C., Yin, C.-F., Chang, Y., Fan, Y.-C., Lin, S.-H., Wu, Y., Huang, H., & Juan, H. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05256-z · Cited by 20
Schnappauf, O., Beyes, S., Dertmann, A., Freihen, V., Frey, P., Jägle, S., Rose, K., Michoel, T., Grosschedl, R., & Hecht, A. (2016) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2016.08.002 · Cited by 18
Cong, Z., Li, Q., Yang, Y., Guo, X., Cui, L., & You, T. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.04.190 · Cited by 20
Chromatin Mechanisms Driving CancerPreprint
Gryder, B. E., Scacheri, P. C., Ried, T., & Khan, J. I. (2021) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a040956 · Cited by 20
Single-Cell Epigenomics Reveals Mechanisms of Cancer Progression
LaFave, L. M., Savage, R. E., & Buenrostro, J. D. (2022) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070620-094453 · Cited by 20
Inflammatory Immune-Associated eRNA: Mechanisms, Functions and Therapeutic Prospects
Wan, L., Li, W., Meng, Y., Hou, Y., Chen, M., & Xu, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.849451 · Cited by 20
Takayama, K., & Inoue, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1024600 · Cited by 19
Harnessing the MYB-dependent TAL1 5’super-enhancer for targeted therapy in T-ALL
Smith, C. L., Touzart, A., Simonin, M., Quang, C. T., Hypolite, G., Latiri, M., Andrieu, G. P., Balducci, E., Dourthe, M.-É., Goyal, A., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01701-x · Cited by 19
Mizokami, H., Okabe, A., Choudhary, R., Mima, M., Saeda, K., Fukuyo, M., Rahmutulla, B., Seki, M., Goh, B.-C., Kondo, S., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105057 · Cited by 20
An isoform-specific C/EBPβ inhibitor targets acute myeloid leukemia cells
Jakobs, A., Uttarkar, S., Schomburg, C., Steinmann, S., Coulibaly, A., Schlenke, P., Berdel, W. E., Müller‐Tidow, C., Schmidt, T. J., & Klempnauer, K.-H. (2016) · Leukemia · doi:10.1038/leu.2016.16 · Cited by 19
Noncoding RNA transcription at enhancers and genome folding in cancer
Isoda, T., Morio, T., & Takagi, M. (2019) · Cancer Science · doi:10.1111/cas.14107 · Cited by 19
CRISPR and transposon in vivo screens for cancer drivers and therapeutic targets
Noorani, I., Bradley, A., & Rosa, J. D. L. (2020) · Genome biology · doi:10.1186/s13059-020-02118-9 · Cited by 20
The Role of rDNA Clusters in Global Epigenetic Gene Regulation
Tchurikov, N. A., & Kravatsky, Y. V. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.730633 · Cited by 23
Metadata
- Authors
- Mansour, M. R., Abraham, B. J., Anders, L., Berezovskaya, A., Gutierrez, A., Durbin, A. D., Etchin, J., Lawton, L., Sallan, S. E., Silverman, L. B., Loh, M. L., Hunger, S. P., Sanda, T., Young, R. A., & Look, A. T.
- Affiliations
- Harvard University (US)
- Whitehead Institute for Biomedical Research (US)
- Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
- Boston Children's Hospital (US)
- University of California, San Francisco (US)
- Children's Hospital Colorado (US)
- National University of Singapore (SG)
- Corresponding author
- Abraham, Brian J.
- Anders, Lars
- Young, Richard A.
- Look, A. Thomas
- ORCID
- Venue
- Science
- Published
- 2014-12-12
- Volume
- 346
- Issue
- 6215
- Pages
- 1373-1377
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4720521
- OpenAlex
- W2082414039
- Cited by
- 801
- References
- 46
- Citations by year
- 2026: 32 · 2025: 49 · 2024: 61 · 2023: 77 · 2022: 84 · 2021: 85 · 2020: 80 · 2019: 62 · 2018: 65 · 2017: 77 · 2016: 76 · 2015: 49 · 2014: 4
- FWCI
- 28.17
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- UCL Discovery (University College London) (submittedVersion)
- PMC
- Funders
- National Human Genome Research Institute (R01HG002668)
- National Cancer Institute (R21CA167124, CA114766, CA30969, R01CA176746, CA‐98413, U10CA098413, U24CA114766, U10CA030969, P01CA068484, CA 29139, R01CA120215, 5P01CA68484, U10CA029139, U10CA098543, P01CA109901, CA167124, CA120215, CA-98543, P30CA014051)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Keywords
- super-enhancers, T-cell acute lymphoblastic leukemia, MYB transcription factors, somatic mutations, H3K27 acetylation, CBP, RUNX1, GATA3, transcriptional regulation, oncogene expression
- MeSH terms
- T-Cell Acute Lymphocytic Leukemia Protein 1, Acetylation, Base Sequence, Binding Sites, Enhancer Elements, Genetic, Histones, Humans, Molecular Sequence Data, Mutation, Oncogenes, Proto-Oncogene Proteins, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins c-myb, DNA, Intergenic, Cell Line, Tumor, Basic Helix-Loop-Helix Proteins, Basic Helix-Loop-Helix Transcription Factors, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, INDEL Mutation, Protein Interaction Domains and Motifs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
